Key Messages
- CADTH recommends that Firdapse be reimbursed by public drug plans for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) only if certain conditions are met.
- Firdapse should only be covered to treat patients who are 18 years of age and older and have LEMS.
- Firdapse should only be reimbursed if the patient is under the care of a neurologist with expertise in managing LEMS and if the price of Firdapse is reduced.